Curating from trusted global sources…
5 briefings · “growth”
One U.S. biotech chooses Hong Kong for investors and proximity to Chinese pharma partners, reshaping where growth capital starts.
The move targets price and brand control, and it signals how Nike plans to restart growth in a messy market.
What China’s first approval ahead of major regulators means for biopharma strategy, timelines, and competitive pressure.
How a Thai oil refiner pulled itself back from debt in the 2000s and reshaped its growth playbook.
The milestone, led by BYD's Seagull at Camacari, lands as Europe weighs its response to a surge in Chinese EVs.
